drugset
drugset / Trial / NCT02436707

Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

NCT02436707 ↗

Phase 2 Active not recruiting 129 enrolled Canadian Cancer Trials Group Janssen, LP · collabKaryopharm Therapeutics Inc · collabRoche Pharma AG · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to find out what effects new combinations of treatment will have this disease. New promising treatment strategies will be added to this study as they are available to be compared against the standard treatment.

Timeline

Start
2015-10-27
Primary completion
2026-06-30
Completion
2026-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 35 mg/m2 Intravenous
Subject Cisplatin Other / unclassified 75 mg/m2 Intravenous
Subject Cyclophosphamide Other / unclassified 1.75 g/kg Intravenous
Subject Dexamethasone Small molecule 40 mg Oral
Subject Etoposide Small molecule 350 mg/m2 Intravenous
Subject Gemcitabine Small molecule 1000 mg/m2 Intravenous
Subject Ibrutinib Small molecule 560 mg Oral
Subject Rituximab Monoclonal antibody 375 mg/m2 Intravenous
Subject Selinexor Other / unclassified 40 mg Oral
Background 2-MERCAPTOETHANESULFONIC ACID Small molecule 1.75 g/kg Intravenous
Background G-CSF Unknown 300 ug Subcutaneous
Background G-CSF Unknown 480 ug Subcutaneous
Background G-CSF Unknown 600 ug Subcutaneous

Indications

lymphoma